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Letter to the Editor
Thrombohemostatic disorders in the new emerging H7N9 
influenza
Dear editor,
An emerging infectious disease is usually problematic in 
medicine. Cross-species zoonosis is a current focus. The 
newly emerging H7N9 influenza infection is an atypical 
influenza that was detected early in 2013.1 The disease 
was first reported in China and since then cases have been 
reported from many different provinces.1 According to the 
World Health Organization official report, by the end of May 
2013, there were 132 accumulated cases.2 Infection can be 
seen in both genders and in all age groups. This disease 
is of concern because of the possibility that it may cause 
a worldwide pandemic. The H7N9 influenza virus, which 
seems to have originated in birds, causes problematic 
infections in humans.3,4 H7N9 influenza can display both 
a classic acute respiratory illness as well as many atypical 
clinical symptoms, including hematological disorders. 
Thrombohemostasis disorders are of great concern5 and will 
be discussed further in this letter to the editor. 
Platelet disorders are very common laboratory findings of 
the new H7N9 influenza virus.5 Joob & Wiwanitkit were the 
first to call attention to this problem in their recent article 
published in the journal Platelets.6 According to a large report 
on 111 cases of infection, the finding of thrombocytopenia is 
common.7 Concerns are raised about its clinical importance. 
In another report, a drop in platelet counts are observed 
within 2 to 3 days after confirmation of H7N9 infection.8 
H7N9 influenza virus might carry out several pathological 
processes to induce thrombocytopenia. Since the induction 
of thrombocytopenia, as a result of immunopathology, was 
detected in previous emerging influenza, such as the H1N1 
swine flu,9 it could be possible to see the same in H7N9 
influenza.
Focusing on the clinical importance, the main question 
is whether thrombocytopenia will cause bleeding or not. 
Up to now, there is still no report of overt bleeding as a 
complication of the H7N9 influenza. Based on the available 
data, the decreased platelet level is small (platelet counts 
in reported cases are between 71 and 75  ×  109/L whereas 
the reference range is 85-303 × 109/L).10 Nevertheless, 
whether the H7N9 can induce thrombocytopenia or not is 
still questionable. In fact, Lu et al. investigated four patients 
with one suffering from chronic hepatic schistosomiasis and 
a possible thrombocytopenic effect.8 Similarly, Chen et al. 
investigated four patients with one suffering from chronic 
hepatitis B virus infection, and a possible thrombocytopenic 
effect.11 Thus, it is recommended to monitor the platelet 
count in patients infected with H7N9 influenza as it may 
reflect on the prognosis.
There is only one report that investigated coagulation 
screening in patients infected by H7N9 influenza.11 The 
available data relates to prothrombin time (PT) and activated 
thromboplastin time (aPTT). According to the report by 
Chen et al., some cases have abnormal PT and aPTT.11 The 
PT and aPTT are prolonged by about two and three times 
their normal time, respectively.11 Nevertheless, Chen et al. 
studied only four patients and half of them had underlying 
medical disorders that affect coagulation (chronic hepatitis 
B with possible coagulation disorder and chronic rheumatic 
heart disease with aortic and mitral valve replacements, and 
receiving anticoagulant therapy). Chen et al. also reported 
on disseminated intravascular coagulopathy (DIC). Positive 
D-dimer tests can be seen in almost all infected cases.10 DIC 
is observed as disease progresses.11
In conclusion, abnormalities in thrombohemostasis can 
be seen in patients infected by H7N9 influenza. It is important 
to monitor the thrombohemostasis in these patients.
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